Cart is empty
View Cart
Subtotal: $0.00
JOIN NOW!
  • ABOUT US
    • Board of Directors
    • Benefits
    • Volunteering
      • Volunteer Opportunities
      • EDEI Committee
      • Education
      • Emerging Leaders
      • Local GAMP CoP
      • Membership
      • Product Show
      • Social
      • Student Development
      • Women in Pharma®
    • Students
      • Student Chapters
      • Career Workshop
      • Scholarships
    • Chapter Awards
      • NEW Chapter Awards 2024
    • Sponsors
    • Contact Us
  • EVENTS
    • Chapter Calendar
    • Educational Programs
    • Social Events
    • Student Activities
    • Product Show
    • Past Events
  • RESOURCES
    • Scholarship Foundation
      • Scholarship Application
    • Podcast
    • Documents
    • Chapter YouTube Channel
    • ISPE Publications
    • ISPE Guidance Documents
    • Member Directory
    • ISPE Training
    • ISPE Communities of Practice
  • BLOG
    • Boston Chapter Blog
      • Contribute
    • ISPE Blog
  • CAREERS
    • Job Board
    • Post a Job
  • Gallery
  • SCHOLARSHIP FOUNDATION
    • About the Foundation
    • Apply for a Scholarship
    • Donate
  • ABOUT US
    • Board of Directors
    • Benefits
    • Volunteering
      • Volunteer Opportunities
      • EDEI Committee
      • Education
      • Emerging Leaders
      • Local GAMP CoP
      • Membership
      • Product Show
      • Social
      • Student Development
      • Women in Pharma®
    • Students
      • Student Chapters
      • Career Workshop
      • Scholarships
    • Chapter Awards
      • NEW Chapter Awards 2024
    • Sponsors
    • Contact Us
  • EVENTS
    • Chapter Calendar
    • Educational Programs
    • Social Events
    • Student Activities
    • Product Show
    • Past Events
  • RESOURCES
    • Scholarship Foundation
      • Scholarship Application
    • Podcast
    • Documents
    • Chapter YouTube Channel
    • ISPE Publications
    • ISPE Guidance Documents
    • Member Directory
    • ISPE Training
    • ISPE Communities of Practice
  • BLOG
    • Boston Chapter Blog
      • Contribute
    • ISPE Blog
  • CAREERS
    • Job Board
    • Post a Job
  • Gallery
  • SCHOLARSHIP FOUNDATION
    • About the Foundation
    • Apply for a Scholarship
    • Donate
Featured Image

What is Gene Therapy?

  • Posted by ISPE Boston
  • On September 7, 2017
Human gene therapy is the administration of genetic material to modify or manipulate the expression of a gene product or to alter the biological properties of living cells for therapeutic use. Gene therapy is a technique that modifies a person’s genes to treat or cure disease. Gene therapies can work by several mechanisms: Replacing a […]
Read More
 
Featured Image

Novartis CAR-T Gene Therapy Wins FDA Approval

  • Posted by ISPE Boston
  • On September 7, 2017
The FDA issued a historic action on August 30, making the first gene therapy available in the United States. With its approval of Novartis’ Kymriah therapy for a form of acute lymphoblastic leukemia (ALL), the FDA ushered in a new approach to the treatment of cancer and other serious and life-threatening diseases. “We’re entering a […]
Read More
 
Featured Image

Ironwood Pharmaceuticals Announces FDA Approval for Duzallo

  • Posted by ISPE Boston
  • On August 23, 2017
Cambridge-based Ironwood Pharmaceuticals has announced Duzallo was approved by the FDA as a treatment for hyperuricemia, or elevated serum uric acid levels (sUA) in the blood, associated with gout. Duzallo is the first drug that combines the current standard of care for the treatment of hyperuricemia associated with gout, the xanthine oxidase inhibitor (XOI) allopurinol, […]
Read More
 1
Featured Image

What is the Innate Immune System?

  • Posted by ISPE Boston
  • On August 17, 2017
The innate immune system is the body’s first line of immunological response and the master regulator of subsequent immune activity. In cancer, the innate immune system mediates presentation of tumor antigens, priming and activation of tumor-specific immune cells that enable optimal development of adaptive anti-tumor immunity. Existing immunotherapies are mostly focused on harnessing the adaptive […]
Read More
 1
Featured Image

IFM Therapeutics Acquired by Bristol-Myers Squibb

  • Posted by ISPE Boston
  • On August 17, 2017
Bristol-Myers Squibb (BMS) has agreed to pay $300 million to acquire Cambridge-based IFM Therapeutics, a venture-backed startup founded in 2015 focused on innate immunity and the role it plays in regulating the immune system. IFM’s team has discovered and developed small molecules that modulate novel targets in the innate immune system as next-generation therapies for […]
Read More
 1
Featured Image

Avecia Expanding Drug Manufacturing Facility in Milford

  • Posted by ispeblog
  • On July 19, 2017
Avecia, a pharmaceutical manufacturer in Milford, says it is building what will become the largest manufacturing site in the world for a specialized drug ingredient called oligonucleotide. The expansion, which will add 20,000 square feet of space, will more than double the Milford site’s total capacity, the company said in a recent announcement. Oligonucleotide, a […]
Read More
 
Featured Image

MassBioEd Predicts Job Trends Forecast for the Biopharma Industry

  • Posted by ispeblog
  • On July 19, 2017
The MassBioEd Foundation released its 2017 Annual Job Trends Forecast at Life Sciences Workforce 2017, its second annual conference on life sciences workforce trends.  The event was held at Northeastern University and featured twenty-seven industry and higher education speakers, as well as Lt. Governor Karyn Polito, who provided keynote remarks. The Forecast included the following […]
Read More
 
Featured Image

Novartis Gene Therapy Recommended for Approval by FDA Advisory Committee

  • Posted by ispeblog
  • On July 17, 2017
Novartis has announced that the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisagenlecleucel), an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of children and young adults with B-cell acute lymphoblastic leukemia (ALL) that has relapsed or resisted treatment (r/r). A Biologics License Application (BLA) for this […]
Read More
 

What is Novartis CAR-T Therapy?

  • Posted by ispeblog
  • On July 17, 2017
CAR-T (chimeric antigen receptor T cell) therapy is different from typical small molecule or biologic therapies because it is manufactured for each individual patient using their own cells. During the treatment process, T cells are drawn from a patient’s blood and reprogrammed in a manufacturing facility to create T cells that are genetically coded to […]
Read More
 
Featured Image

Alnylam and Sanofi Genzyme Report Strong Results from Phase 2 Trial of RNAi Treatment for Hemophilia

  • Posted by ispeblog
  • On July 12, 2017
Alnylam and Sanofi Genzyme have announced new positive results from the ongoing Phase 2 study with fitusiran in patients with hemophilia A and B, with or without inhibitors. Fitusiran is an investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of patients with hemophilia A and B, that is designed to lower levels of AT […]
Read More
 
Page 52 of 56«‹5051525354›»
Post Categories
  • Podcasts (1)
  • Industry Buzz (557)
  • Chapter News (536)
  • Knowledge & Training (79)
  • Students & YP (78)
  • Career Tools (13)
Get Updates via Email




Scroll
Follow Us
Search this Site
@2024 ISPE Boston Chapter. All rights reserved.